MiNK Therapeutics/INKT

$0.88

0.52%
-
1D1W1MYTD1YMAX

About MiNK Therapeutics

MiNK Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. iNKT cells are a distinct T cell population that combine durable memory responses with the rapid cytolytic features of natural killer cells. iNKT cells offer distinct therapeutic advantages as a platform for allogeneic therapy in that the cells naturally home to tissues, aid clearance of tumors and infected cells and suppress Graft versus Host Disease. Its platform is designed to facilitate scalable and reproducible manufacturing for off-the-shelf delivery. Its product candidate, agenT-797, is an off-the-shelf, allogeneic, native iNKT cell therapy. Its engineered programs are MiNK-413, an IL-15 armored CAR-iNKT program targeting B cell maturation antigen, and MiNK-215, an IL-15 armored tumor stromal targeting FAP-CAR-iNKT program.

Ticker

INKT

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Jennifer Buell

Employees

31

Headquarters

New york, United States

INKT Metrics

BasicAdvanced
$31.76M
Market cap
-
P/E ratio
-$0.65
EPS
-
Beta
-
Dividend rate
$31.76M
$3.34
$0.75
98.43K
0.316
-172.59%
-2,317.47%
21.36%

What the Analysts think about INKT

Analyst Ratings

Majority rating from 4 analysts.
Buy

Price Targets

Average projection from 3 analysts.
809.09% upside
High $9.00
Low $7.00
$0.88
Current price
$8.00
Average price target

INKT Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
0% profit margin
QuarterlyAnnual
Q4 23
QoQ growth
Revenue
$0
-
Net income
$-5.4M
5.88%
Profit margin
0%
-

INKT Earnings Performance

Earnings per share (EPS)

Company profitability
Missed by 4.35%
QuarterlyAnnual
Q1 23
Q2 23
Q3 23
Q4 23
Q1 24
Actual
-$0.17
-$0.18
-$0.15
-$0.16
-
Expected
-$0.24
-$0.20
-$0.18
-$0.15
-$0.15
Surprise
-28.42%
-8.86%
-17.81%
4.35%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

FAQs

What’s the current market cap for MiNK Therapeutics stock?

MiNK Therapeutics (INKT) has a market cap of $30.25M as of April 20, 2024.

What is the P/E ratio for MiNK Therapeutics stock?

The price to earnings (P/E) ratio for MiNK Therapeutics (INKT) stock is 0 as of April 20, 2024.

Does MiNK Therapeutics stock pay dividends?

No, MiNK Therapeutics (INKT) stock does not pay dividends to its shareholders as of April 20, 2024.

When is the next MiNK Therapeutics dividend payment date?

MiNK Therapeutics (INKT) stock does not pay dividends to its shareholders.

What is the beta indicator for MiNK Therapeutics?

MiNK Therapeutics (INKT) does not currently have a Beta indicator.

What is the MiNK Therapeutics stock price target?

The target price for MiNK Therapeutics (INKT) stock is $8, which is 809.09% above the current price of $0.88. This is an average based on projections from 3 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell MiNK Therapeutics stock

Buy or sell MiNK Therapeutics stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing